This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Impact of molecular imaging on the diagnostic process in a memory clinic


Ossenkoppele, Rik, Prins, Niels D., Pijnenburg, Yolande A.L., Lemstra, Afina W., van der Flier, Wiesje M., Adriaanse, Sofie F., Windhorst, Albert D., Handels, Ron L.H., Wolfs, Claire A.G., Aalten, Pauline, Verhey, Frans R.J., Verbeek, Marcel M., van Buchem, Mark A., Hoekstra, Otto S., Lammertsma, Adriaan A., Scheltens, Philip, van Berckel, Bart N.M.


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 9, No.: 4, Pages.: 414-421

Year of Publication



Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year clinical follow-up data were available for 39 patients. Parametric PET images were assessed visually and results were reported to the neurologists responsible for the initial diagnosis. Outcome measures were (change in) clinical diagnosis and confidence in that diagnosis before and after disclosing PET results.; Results: [(11)C]PIB scans were positive in 40 of 66 (61%) patients with a clinical diagnosis of Alzheimer’s disease (AD), 5 of 18 (28%) patients with frontotemporal dementia (FTD), 4 of 5 (80%) patients with Lewy body dementia, and 3 of 10 (30%) patients with other dementias. [(18)F]FDG uptake patterns matched the clinical diagnosis in 38 of 66 (58%) of AD patients, and in 6 of 18 (33%) FTD patients. PET results led to a change in diagnosis in 35 (23%) patients. This only occurred when prior diagnostic certainty was <90%. Diagnostic confidence increased from 71 ± 17% before to 87 ± 16% after PET (p < .001). Two-year clinical follow-up (n = 39) showed that [(11)C]PIB and [(18)F]FDG predicted progression to AD for patients with mild cognitive impairment, and that the diagnosis of dementia established after PET remained unchanged in 96% of patients.; Conclusions: In a memory clinic setting, combined [(11)C]PIB and [(18)F]FDG PET are of additional value on top of the standard diagnostic work-up, especially when prior diagnostic confidence is low.; Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Ossenkoppele_2013, doi = {10.1016/j.jalz.2012.07.003}, url = {}, year = 2013, month = {jul}, publisher = {Elsevier {BV}}, volume = {9}, number = {4}, pages = {414--421}, author = {Rik Ossenkoppele and Niels D. Prins and Yolande A.L. Pijnenburg and Afina W. Lemstra and Wiesje M. van der Flier and Sofie F. Adriaanse and Albert D. Windhorst and Ron L.H. Handels and Claire A.G. Wolfs and Pauline Aalten and Frans R.J. Verhey and Marcel M. Verbeek and Mark A. van Buchem and Otto S. Hoekstra and Adriaan A. Lammertsma and Philip Scheltens and Bart N.M. van Berckel}, title = {Impact of molecular imaging on the diagnostic process in a memory clinic}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


accuracy, aged, alzheimer disease, aniline compounds, brain, carbon radioisotopes, dementia, diagnosis, diagnosis, differential, diagnostic, diagnostic use, disease progression, early diagnosis, etiology, female, fluorine radioisotopes, fluorodeoxyglucose f18, france, frontotemporal dementia, humans, lewy body disease, male, memory disorders, middle aged, molecular imaging, outpatient clinics hospital, prospective studies, psychology, radionuclide imaging, radiopharmaceuticals, sensitivity and specificity, statistics & numerical data, thiazoles, treatment outcome

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Cohort Study

Type of Outcomes



Specialist Dementia Centre Care / Memory Clinic

Type of Interventions

Diagnostic Target Identification